Variables | Values |
Variants of AAV (n, %) MPA GPA EGPA Serotype of AAV (n, %) MPO-ANCA positive PR3-ANCA positive Age (years) Male gender (n, %) General manifestations (n, %) Skin involvement (n, %) ENT involvement (n, %) Cardiovascular involvement (n, %) Abdominal involvement (n, %) Nervous systemic involvement (n, %) Pulmonary involvement (n, %) Alveolar hemorrhage (n, %) Interstitial lung disease (n, %) Kidney involvement (n, %) Proteinuria and /or hematuria (n, %) SCR (μmol/L) Hemoglobin (g/L) Serum albumin (g/L) Complement C3 (g/L) (0.8 - 1.52 g/L) Complement C4 (g/L) (0.16 - 0.38 g/L) BVAS Immunosuppressive treatment (n, %) Death (n, %) Infection Follow-up time (months) |
258 (73.9) 74 (21.2) 17 (4.9)
316 (90.5) 33 (9.5) 63.6 ± 12.7 165 (47.3) 242 (69.3) 22 (6.3) 15 (4.3) 112 (32.1) 100 (28.7) 39 (11.2) 164 (47.0) 48 (13.8) 102 (29.2) 287 (82.2) 258 (73.9) 223 (77, 575.5) 91 (75.5, 109.0) 30 (26, 35) 0.79 (0.66, 0.93) 0.22 (0.17, 0.27) 15 (10, 18) 207 (59.3) 138 (42.7) 73 (52.9) 23.0 (7.5, 45.7) |